Nectin-4/CD137 (via BT7480)
E1266367
UNEXPLORED
Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Nectin-4/CD137 (via BT7480) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T17377779 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: Nectin-4/CD137 (via BT7480) Context triple: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
E.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: Nectin-4/CD137 (via BT7480) Target entity description: Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
E.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.